Back to results
US 2025/0144116 A1Published application
Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
AssigneeInsmed Incorporated
InventorsAriel TEPER, Andrea MAES, Marcela VERGARA, Christina RAMIREZ
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating hidradenritis suppurativa with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1, 4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (1) or a pharmaceutically acceptable salt thereof. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1, 3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib).
Claims158
A method of treating hidradenitis suppurativa (HS) in a subject in need thereof, comprising:
- administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is
- R2 is hydrogen, F, Cl, Br, OSO2C1-3alkyl, or C1-3alkyl;
- R3 is hydrogen, F, Cl, Br, CN, CF3, SO2C1-3alkyl, CONH2 or SO2NR4R5,
- wherein R4 and R5 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine or piperidine ring;
- or
- X is O, S or CF2;
- Y is O or S;
- Q is CH or N;
- R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from the group consisting of OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, and tetrahydropyran;
- and
- R7 is hydrogen, F, Cl or CH3,
- thereby treating hidradenitis suppurativa in the subject.
11 more elements
Dependencies are inferred from the claim text.